Market Overview:
The global 5 nucleotidase market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for novel therapies, and growing focus on personalized medicine. The global 5 nucleotidase market is segmented by type into CPX-006, IPH-53, AB-680, BMS-986179 and others. The CPX-006 segment is expected to account for the largest share of the global 5 nucleotidase market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this segment can be attributed to its ability to inhibit tumor cell proliferation and induce apoptosis in cancer cells. The global 5 nucleotidase market is also divided by application into colorectal cancer, fallopian tube cancer, gastric cancer metastatic colorectal cancer and others. Colorectal Cancer accounted for the largest share of this market in 2017 owingto its high prevalence across all regions studied herein North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA).
Product Definition:
5 Nucleotidase is an enzyme that catalyzes the hydrolysis of 5-phosphomonoesters of nucleosides to the corresponding free nucleotides and inorganic phosphate. It is found in a number of different tissues, including liver, pancreas, and kidney. The importance of 5 Nucleotidase is that it plays a role in signal transduction by breaking down extracellular ATP to AMP. This allows for the activation of various enzymes and proteins involved in cellular signaling pathways.
CPX-006:
CPX-006 is a novel, potent and selective 5 nucleotidase inhibitor. It has been shown to have an IC 50 of 0.1 uM in human platelets and 1 uM in HepG2 cells with no cytotoxic effects at these concentrations.
IPH-53:
Isopropylthio-D-riboside is a nucleotide sugar used in the preparation of pharmaceutical drugs. It has been studied that Isopropylthio-D-riboside helps to enhance the activity of DNA polymerase and reverse transcriptase enzymes, which are involved in gene expression. The enzyme also enhances protein synthesis from RNA by enhancing catalytic conversion between thiols and S-glutathione.
Application Insights:
The application segment includes colorectal cancer, fallopian tube cancer, gastric cancer, and others. The market for 5 nucleotidase is expected to witness significant growth owing to the increasing incidence of colorectal cancer which is the second most common cause of cancers deaths in developed countries. As per the World Health Organization (WHO), over 1 million people die due to colorectal Cancer every year globally and around 940 thousand cases are registered each year. It has been estimated that by 2030, over 250 thousand new cases will be reported globally every year along with an increase in mortality rate due to this disease. Thus rise in incidence coupled with awareness regarding early diagnosis is anticipated to boost demand for 5 Nucleotidase enzyme replacement therapy during the forecast period.
Regional Analysis:
North America dominated the global 5 nucleotidase market in 2017. This is attributed to the presence of a large number of cancer patients, increased research activities by various companies and universities, and high adoption of 5-Nucleotide Therapeutics (NAT) for treatment of cancer. The U.S.
Growth Factors:
- Increasing demand for nucleotidases in the pharmaceutical and biotechnology industries for research and development purposes.
- Growing demand for nucleotidases from the food industry as a result of their increasing use in food processing and production.
- Rising incidence of genetic disorders that can be treated with nucleotidase therapies, driving growth in the market.
- Technological advancements that have made nucleotidase enzymes more efficient, accurate, and reliable, boosting their adoption across various industries.
Scope Of The Report
Report Attributes
Report Details
Report Title
5 Nucleotidase Market Research Report
By Type
CPX-006, IPH-53, AB-680, BMS-986179, Others
By Application
Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Metastatic Colorectal Cancer, Others
By Companies
Bristol-Myers Squibb Co, Corvus Pharmaceuticals Inc, Innate Pharma SA, MedImmune LLC, Surface Oncology Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global 5 Nucleotidase Market Report Segments:
The global 5 Nucleotidase market is segmented on the basis of:
Types
CPX-006, IPH-53, AB-680, BMS-986179, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Colorectal Cancer, Fallopian Tube Cancer, Gastric Cancer, Metastatic Colorectal Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb Co
- Corvus Pharmaceuticals Inc
- Innate Pharma SA
- MedImmune LLC
- Surface Oncology Inc
Highlights of The 5 Nucleotidase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CPX-006
- IPH-53
- AB-680
- BMS-986179
- Others
- By Application:
- Colorectal Cancer
- Fallopian Tube Cancer
- Gastric Cancer
- Metastatic Colorectal Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the 5 Nucleotidase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
5 nucleotidase is an enzyme that catalyzes the hydrolysis of 5'-phosphodiester bonds in DNA.
Some of the major companies in the 5 nucleotidase market are Bristol-Myers Squibb Co, Corvus Pharmaceuticals Inc, Innate Pharma SA, MedImmune LLC, Surface Oncology Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 5 Nucleotidase Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 5 Nucleotidase Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 5 Nucleotidase Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the 5 Nucleotidase Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global 5 Nucleotidase Market Size & Forecast, 2020-2028
4.5.1 5 Nucleotidase Market Size and Y-o-Y Growth
4.5.2 5 Nucleotidase Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CPX-006
5.2.2 IPH-53
5.2.3 AB-680
5.2.4 BMS-986179
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Colorectal Cancer
6.2.2 Fallopian Tube Cancer
6.2.3 Gastric Cancer
6.2.4 Metastatic Colorectal Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global 5 Nucleotidase Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 5 Nucleotidase Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CPX-006
9.6.2 IPH-53
9.6.3 AB-680
9.6.4 BMS-986179
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Colorectal Cancer
9.10.2 Fallopian Tube Cancer
9.10.3 Gastric Cancer
9.10.4 Metastatic Colorectal Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CPX-006
10.6.2 IPH-53
10.6.3 AB-680
10.6.4 BMS-986179
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Colorectal Cancer
10.10.2 Fallopian Tube Cancer
10.10.3 Gastric Cancer
10.10.4 Metastatic Colorectal Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CPX-006
11.6.2 IPH-53
11.6.3 AB-680
11.6.4 BMS-986179
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Colorectal Cancer
11.10.2 Fallopian Tube Cancer
11.10.3 Gastric Cancer
11.10.4 Metastatic Colorectal Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CPX-006
12.6.2 IPH-53
12.6.3 AB-680
12.6.4 BMS-986179
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Colorectal Cancer
12.10.2 Fallopian Tube Cancer
12.10.3 Gastric Cancer
12.10.4 Metastatic Colorectal Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CPX-006
13.6.2 IPH-53
13.6.3 AB-680
13.6.4 BMS-986179
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Colorectal Cancer
13.10.2 Fallopian Tube Cancer
13.10.3 Gastric Cancer
13.10.4 Metastatic Colorectal Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 5 Nucleotidase Market: Competitive Dashboard
14.2 Global 5 Nucleotidase Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb Co
14.3.2 Corvus Pharmaceuticals Inc
14.3.3 Innate Pharma SA
14.3.4 MedImmune LLC
14.3.5 Surface Oncology Inc
